| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
OneMedNet Corp Class A Common Stock$0.63
+0.03 (+4.8%)
Market Cap
43.37 M
EPS
-0.05
P/E Ratio
-16.85 $
Value Trade
112.69 K
SEC Financials
Q3 2025Dilution Risk
Revenue
177.00 K
R&D Expenses
323.00 K
Total Assets
1.51 M
Total Liabilities
5.45 M
Equity
-3.94 M
D/E Ratio
12,345
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
149.00 K
Monthly Burn
745.00 K
Runway
0 mo
Burn Trend
StableSEC Filing
Nov 14, 2025
Overview
Volume
6.83 M
52 Week Range
0.30 - 4.22
% held by Insiders
71.13 %
% held by Institutions
24.54 %
Enterprise Value
43.25 M
Total Shares
54.37 M
Short %
1.82 %
Float Shares
18.98 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for OneMedNet Corp Class A Common Stock
35Total events
0Upcoming
8Tier-1 (high impact)
2021 – 2026Coverage
Event history 2
TBD
◆Quarterly UpdateCorporate
Subscribe to view catalyst details
TBD
▲Quarterly UpdateCorporate
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ONMD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
ONMD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-ONMD
Jul 28, 2026▲ +4.8%today
OneMedNet Secures $11.5+ Million Agreement to Supply Regulatory-Grade Real-World Data for Foundational AI Model Development
OneMedNet Corporation has announced an agreement valued at over $11.5 million to supply regulatory-grade Real-World Data for AI model development. The company will provide high-quality, de-identified healthcare data, enhancing its capabilities in delivering essential data for foundational AI innovations. This agreement is expected to strengthen OneMedNet's commercial momentum and expand its extensive network.
Read more →-ONMD
Jun 10, 2026▼ -7.1%on this news
OneMedNet Executes on Growth Strategy: Secures Over $3 Million in New Bookings, Surpassing Full-Year 2025
OneMedNet Corporation has announced over $3 million in new bookings for 2026, surpassing its total bookings for the entirety of 2025. The company anticipates recognizing most of these bookings as revenue by the end of Q3 2026, reflecting strong demand for its AI-driven Real-World Data platform. This growth is attributed to new customer acquisitions and expanded engagements within the life sciences sector.
Read more →-ONMD
Jun 3, 2026OneMedNet Surpasses 90 Million Patient Journeys and 270 Million Studies within its Network
OneMedNet Corporation has announced significant milestones, surpassing 90 million patient journeys and 270 million studies in its iRWD™ Network. The company has expanded its healthcare partner network to over 2,300 sites, reflecting its commitment to enhancing Real-World Data availability. This growth aligns with OneMedNet's strategic priorities to create long-term value for shareholders.
Read more →-ONMD
Feb 27, 2026▲ +44.6%on this news
OneMedNet Announces Next Phase of Commercial Launch with its Real-World Data (RWD) Platform powered by Palantir Foundry
OneMedNet Corporation announced the next phase of its commercial launch for its Real-World Data (RWD) platform powered by Palantir Foundry. Following successful demonstrations, the company is converting customer evaluations into subscriptions, which are expected to drive significant recurring revenue. The platform offers unique real-time data access and enhanced analytical capabilities, benefiting life sciences and healthcare organizations.
Read more →-ONMD
Feb 26, 2026▲ +8.9%on this news· ran to +57% by day 1shared move
OneMedNet Partners with ViuHealth to Enhance Autoimmune Dataset Scale, Accelerating Recurring Revenue from Life Sciences and AI Customers
OneMedNet Corporation has partnered with ViuHealth to enhance its autoimmune dataset through the iRWD platform. This collaboration aims to provide comprehensive, longitudinal data that can accelerate drug discovery and support regulatory initiatives. The partnership is expected to bolster OneMedNet's subscription revenue strategy by integrating high-value data, benefiting both companies and their clients in the life sciences sector.
Read more →-ONMD
Feb 24, 2026OneMedNet Announces Strategic Neuro Data Partnership with Risorius to Advance EEG-Based Digital Biomarkers
OneMedNet Corporation has entered a strategic data licensing agreement with Risorius Co., Ltd. to enhance EEG-based digital biomarkers for CNS indications. The partnership allows Risorius access to large-scale EEG and PSG data, supporting their R&D and AI platform development. The swift execution of the agreement highlights the strong alignment between the two companies and the growing demand for high-quality datasets in the neurotechnology field.
Read more →-ONMD
Feb 12, 2026▲ +18.3%on this news
OneMedNet Reports Record 2025 Bookings of $2.79 Million, Surpassing Prior Year by More Than 4.1X and Accelerating Subscription Transition
OneMedNet Corporation reported record bookings of $2.79 million in 2025, surpassing the previous year's figures by over four times. The company is transitioning from project-based engagements to recurring subscription models, enhancing visibility and long-term value. Early feedback on new subscription offerings powered by Palantir Foundry has been positive, indicating strong momentum heading into 2026.
Read more →-ONMD
Jan 23, 2026OneMedNet Real-World Data Supports FDA 510(k) Clearance of AI-Powered Scaida BrainCT-ICH Software
OneMedNet Corporation announced that its Real-World Data supported mlHealth 360 in obtaining FDA 510(k) clearance for Scaida BrainCT-ICH, an AI software for rapid detection of intracranial hemorrhage. The software analyzes CT scans in about 5.97 seconds, facilitating quicker clinical decisions. This milestone underscores OneMedNet's role as a leading data provider in the healthcare AI sector.
Read more →-ONMD
Jan 16, 2026▲ +5.9%on this newsshared move
OneMedNet Delivers a Real-World Data feed of 1.5M Patients consisting of 4M encounters
OneMedNet Corporation has delivered a significant Real-World Data feed of 1.5 million patients and 4 million encounters to a healthcare analytics organization. This dataset supports enterprise-scale testing and confirms the recipient's platform's ability to manage complex healthcare data. The delivery reinforces OneMedNet's subscription model, enhancing predictable revenue streams and partnerships in the healthcare data market.
Read more →-ONMD
Dec 30, 2024▲ +9.8%on this news
OneMedNet Regains Compliance with NASDAQ Periodic Filing Requirements MINNEAPOLIS
OneMedNet Corporation has announced that it has regained compliance with NASDAQ's periodic filing requirements after submitting its financial reports for the first three quarters of 2024. The company appointed new leadership, including an interim CFO, to enhance its financial reporting processes and has raised over $6.4 million in private placements to improve liquidity. Additionally, OneMedNet is focusing on expanding its presence in the Real World Data market through strategic initiatives and partnerships, including an agreement with Bayer's AI Innovation Platform.
Read more →-ONMD
Nov 27, 2024▼ -8.6%on this news
OneMedNet Announces Receipt of Nasdaq Notice Regarding Delayed Form 10-Q MINNEAPOLIS
OneMedNet Corporation has announced that it received a notice from Nasdaq regarding its failure to timely file its Form 10-Q for the fiscal quarter ended September 30, 2024. The company is currently not in compliance with Nasdaq's listing requirements but has been granted an extension until December 11, 2024, to submit its delinquent filings. While OneMedNet is working diligently to complete these filings, there is no guarantee that it will regain compliance in time to maintain its stock listing.
Read more →-ONMD
Oct 7, 2024▲ +12.4%on this news· ran to +31% by day 1
OneMedNet Announces Board Member Transition to Drive Growth Post-IPO MINNEAPOLIS, OCTOBER 2 , 2024 (GLOBE NEWSWIRE) - OneMedNet Corporation (Nasdaq: ONMD) ("OneMedNet" or the "Company"), the leading curator of regulatory
OneMedNet Corporation has announced a strategic refresh of its Board of Directors following its IPO, aimed at driving growth. The company has expressed gratitude to outgoing members Paul Casey and Erkan Akyuz for their contributions during a pivotal time. New board members include Clarke, an experienced technologist from Microsoft, and Coonse McCraw, a finance expert and HR leader from BMW North America. Their expertise is expected to support market expansion, operational efficiency, and robust financial governance as OneMedNet enters a new phase.
Read more →-ONMD
Sep 26, 2024OneMedNet Announces Additional $1.7 Million Private Placement MINNEAPOLIS
OneMedNet Corporation announced a successful private placement, securing approximately $1.7 million in gross proceeds. The funds will be utilized for working capital and other corporate purposes, including potential investments in Bitcoin. This follows a previous placement in July 2024 that raised $2.7 million, demonstrating ongoing investor interest in the company's growth and strategic direction. The offering included shares, warrants, and pre-funded warrants, emphasizing the company's commitment to expanding its operations in the Real-World Data sector.
Read more →-ONMD
Sep 12, 2024OneMedNet Announces Receipt of Nasdaq Notices Regarding Delayed Forms 10-Q MINNEAPOLIS
OneMedNet Corporation received notices from Nasdaq due to delayed filings of its Form 10-Q for the fiscal quarter ending June 30, 2024. Nasdaq has provided an extension until October 31, 2024, for the company to address its delinquent filings. The company is working with its new auditor to meet this deadline, but they caution that timely compliance cannot be guaranteed. Trading of OneMedNet’s securities will continue uninterrupted on Nasdaq amidst this situation.
Read more →-ONMD
Jul 26, 2024▲ +21.6%on this news· ran to +73% by day 3
OneMedNet Announces $4.6 Million Private Placement Institutional investors include affiliates of Off the Chain Capital and Discovery Capital Management MINNEAPOLIS
OneMedNet Corporation announced the successful closing of a private placement raising approximately $4.6 million from institutional investors, including Off the Chain Capital and Discovery Capital Management. The investment involved the sale of common stock at varying prices per share and is intended to be utilized for working capital and general corporate purposes. Importantly, part of the funds has already been allocated to the purchase of Bitcoin. The offering was conducted under conditions not involving a public offering, adhering to Nasdaq regulations and as part of a strategic approach to enhance the company’s financial position.
Read more →-ONMD
Jun 24, 2024▼ -15.5%on this news
OneMedNet Provides Updates on Auditor Change and Announces Related Receipt of Nasdaq Notice Regarding Delayed Form 10-Q - Regains compliance with Nasdaq minimum closing bid price rule - - Secures financing from instituti
OneMedNet Corporation has announced several corporate updates, including regaining compliance with Nasdaq's minimum bid price rule after maintaining the required stock price. The company appointed a new auditor, WithumSmith+Brown, following the dismissal of its previous auditor, BF Borgers, due to an SEC ban. Additionally, OneMedNet secured a $25 million standby equity purchase agreement with Yorkville Advisors to bolster its growth initiatives. However, the company received a notice from Nasdaq regarding its delayed Form 10-Q filing, putting it temporarily out of compliance.
Read more →-ONMD
Apr 2, 2024▲ +5.5%on this news· ran to +42% by day 1
OneMedNet Announces CEO Succession Plan ~ President, Aaron Green, Assumes Role of Chief Executive Officer ~ ~ CEO, Paul Casey, Announces Retirement and Shift to Active Advisory Role to Guide Transition Successfully ~ ~ C
OneMedNet Corporation has announced the appointment of Aaron Green as the new Chief Executive Officer following the retirement of Paul Casey, who will remain on the Board to ensure a smooth transition. Green brings over 20 years of experience in healthcare IT, having previously led significant initiatives at Change Healthcare and Optum Insights. Under his leadership, OneMedNet added four large strategic partners, nearly doubling its clinical data network, and has reported a year-over-year growth in bookings of 15%. This leadership change is seen as a strategic move to continue the company's operational momentum in the growing field of regulatory-grade imaging data.
Read more →-ONMD
Nov 20, 2023OneMedNet Announces Participation as an Exhibitor in the AI Showcase During the RSNA 2023 Annual Meeting Minneapolis, MN
OneMedNet Corporation (ONMD) has announced its participation as an exhibitor in the AI Showcase at the RSNA 2023 Annual Meeting, taking place from November 26 to 30 in Chicago. The company's technical exhibit will feature its innovative iRWD solution, which uses advanced technology to aggregate and anonymize clinical imaging data. This initiative aims to advance research and development in the life sciences sector by connecting with the radiology community at the largest conference of its kind in the U.S. OneMedNet emphasizes the importance of ethical AI application in medical imaging as part of its commitment to improving healthcare delivery.
Read more →-ONMD
Nov 13, 2023▼ -7.9%on this news
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION Defined terms included below shall have the same meaning as terms defined and included elsewhere in this proxy statement/prospectus. Introduction The following
The article discusses the unaudited pro forma condensed combined financial statements of Data Knights and OneMedNet, illustrating the financial position following their Business Combination. This information is prepared in accordance with Regulation S-X and assumes the merger was consummated on specified dates. It highlights the potential cash and equity positions of the Combined Entity but acknowledges significant uncertainties related to actual outcomes, including stockholder redemptions and the impacts of transaction costs. The unaudited financial information is descriptive and does not provide guarantees of future performance.
Read more →-ONMD
Oct 12, 2023Data Knights Acquisition Corp. Confirms Funding to Extend Period to Consummate Initial Business Combination Minneapolis, MN and London, UK
Data Knights Acquisition Corp. has announced the deposit of $75,000 into its trust account, extending the deadline to complete its initial business combination by one month, from October 11, 2023, to November 11, 2023. This represents the third of nine possible one-month extensions permitted under the company's governing documents. The announcement details the company's ongoing efforts toward its proposed initial public offering, while cautioning that successful completion is not guaranteed.
Read more →-ONMD
Oct 10, 2023DATA KNIGHTS ACQUISITION CORP. PLEASE DO NOT RETURN THE PROXY CARD IF YOU ARE VOTING ELECTRONICALLY. INTERNET/MOBILE – www.cstproxyvote.com Use the Internet to vote your proxy. Have your proxy card available when
Data Knights Acquisition Corp. is preparing for a special shareholder meeting on October 17, 2023, where various proposals will be voted on, including business combination and amendments to the Charter. Shareholders are encouraged to vote electronically or via mail using the enclosed proxy card. If no voting direction is provided, the proxies are instructed to vote in favor of all proposals. The meeting will be held virtually and includes multiple proposals set for approval.
Read more →-ONMD
Sep 25, 2023OneMedNet Corporation and Data Knights Acquisition Corp. Announce Effectiveness of Registration Statement and Date of Data Knights' Special Meeting to Approve Proposed Business Combination Special Meeting of Data Knights
OneMedNet Corporation and Data Knights Acquisition Corp. have announced the effectiveness of the SEC registration statement concerning their proposed business combination. A special meeting for Data Knights' stockholders is scheduled for October 17, 2023, to vote on the merger. Following the completion of the transaction, OneMedNet is expected to operate as a publicly traded company under the ticker 'ONMD' on Nasdaq.
Read more →-ONMD
Aug 11, 2023Data Knights Acquisition Corp. Announces Charter and Trust Agreement Amendments and Extension of Deadline to Complete a Business Combination Minneapolis, MN and London, UK
Data Knights Acquisition Corp. announced that stockholders approved amendments to its charter and trust agreement, allowing for an extension of the deadline to complete a business combination. The amendments permit up to nine one-month extensions until May 11, 2024, by depositing a set amount into the trust account. Despite this, a significant number of stockholders chose to redeem their shares, raising questions about investor confidence. The company remains committed to finalizing the merger within the new extended timeframe.
Read more →-ONMD
Jul 31, 2023Data Knights Acquisition Corp Announces Calling of Special Meeting of Stockholders Minneapolis, MN and London, UK
Data Knights Acquisition Corp announced a special meeting of stockholders on August 11, 2023, to discuss amending its charter regarding merger deadlines. The company is seeking to extend the deadline to complete a business combination with OneMedNet Corporation to May 11, 2024. If the amendment proposals are not approved, there is a risk of liquidation. Additionally, stockholders may redeem their shares for cash during this process.
Read more →-ONMD
Jul 12, 2023Data Knights Acquisition Corp. Confirms Funding to Extend Period to Consummate Initial Business Combination MINNEAPOLIS, MN and LONDON, UK / ACCESSWIRE /
Data Knights Acquisition Corp. has announced the successful deposit of $122,920 into its Trust account, extending the period to complete its initial business combination by one month, now due on August 11, 2023. This extension represents the eighth of the nine monthly extensions allowed under the company's governing documents, indicating ongoing efforts to solidify its strategic objectives. The company continues to navigate forward-looking projections while maintaining transparency regarding potential risks associated with its business strategies.
Read more →-ONMD
Jul 22, 2022OneMedNet Announces Filing of Registration Statement on Form S-4 in Connection with its Proposed Business Combination with Data Knights Acquisition Corp. Reflects continued advancement in the business combination process
OneMedNet Announces Filing of Registration Statement on Form S-4 in Connection with its Proposed Business Combination with Data Knights Acquisition Corp. advancement in the business combination process; transaction remains on schedule to be completed during the second half of 2
Read more →-ONMD
May 20, 2022Extracting and Refining Medical Real World Data P AUL C ASEY CEO J EFFREY Y U , MD F OUNDER & C HAIRMAN APRIL 2022 1 # C o nfi de ntial - N o t f or Di str ibuti on This presentation is for information purposes only to a
Extracting and Refining Medical Real World Data P AUL C ASEY CEO J EFFREY Y U , MD F OUNDER & C HAIRMAN APRIL 2022 1 # C o nfi de ntial - N o t f or Di str ibuti on This presentation is for information purposes only to assist interested parties in making their own evaluation wit
Read more →-ONMD
May 5, 2022Data Knights Acquisition Corp. Confirms Funding to Extend Period to Consummate Initial Business Combination London, UK
Data Knights Acquisition Corp. Confirms Funding to Extend Period to Consummate Initial Business Combination May 5, 2022 - Data Knights Acquisition Corp. ("Data Knights" or the "Company") (Nasdaq: DKDCA, DKDCW), a special purpose acquisition company, today announced the deposit
Read more →-ONMD
Apr 25, 2022OneMedNet, An Expert and Leader in Clinical Imaging Innovation and Data Solutions, to Become Publicly Traded Via Combination with Data Knights Acquisition Corp. ~ Transaction values OneMedNet at pro forma enterprise valu
OneMedNet, An Expert and Leader in Clinical Imaging Innovation and Data Solutions, to Become Publicly Traded Via Combination with Data Knights Acquisition Corp. ~ Transaction values OneMedNet at pro forma enterprise value of $317 million ~ ~ OneMedNet, embraces the promise of
Read more →-ONMD
Jun 22, 2021Data Knights Acquisition Corp. Announces the Separate Trading of Its Class A Common Stock and Warrants MIAMI BEACH, FL / ACCESSWIRE /
Knights Acquisition Corp. Announces the Separate Trading of Its Class A Common Stock and Warrants BEACH, FL / ACCESSWIRE / June 22, 2021 / Data Knights Acquisition Corp. ("Data Knights" or the "Company"), a blank check company formed for the purpose of effecting a merger, capi
Read more →-ONMD
May 11, 2021INDEX TO FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Balance Sheet F-4 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Stockholders and
INDEX TO FINANCIAL STATEMENTS Page Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Balance Sheet F-4 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING To the Stockholders and Board of Directors of Data Knights Acquisition Corp. Opinio
Read more →-ONMD
May 6, 2021Data Knights Acquisition Corp. Announces Pricing of $100,000,000 Initial Public Offering and Nasdaq Listing MIAMI BEACH, FL / ACCESSWIRE /
Knights Acquisition Corp. Announces Pricing of $100,000,000 Initial Public Offering and Nasdaq Listing MIAMI BEACH, FL / ACCESSWIRE / May 6, 2021 / Data Knights Acquisition Corp. ("Data Knights" or the "Company"), announced today that it priced its initial public offering of 1
Read more →Competitive Position
How ONMD ranks across every disease it competes inCompetitive Position is a premium feature
See how ONMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial